person

Robert Litman, MD

Robert Litman

as of 2026-07-01

Monitor this Ask about this

at a glance

Roles: Principal Investigator, Author

KOL signal score 9

1 publications · 1 high-value

Cross-drug reach: 1 competitor drugs

Synthesized from structured facts only — each point cited above.

Profile

Affiliation

CBH Health LLC

Roles

Principal Investigator, Author

KOL signal

Publications

1 (1 high-value)

Trial investigator

yes

Publishes on

1 drugs

Lumateperone (Caplyta)

Trials led

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT01774435Phase 1Completed

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

NCT02008773Phase 2Completed

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

NCT03870880Phase 3Completed

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

NCT03160521Phase 3Completed

Publications & congress

Dopamine D

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019 · high-value

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

publishes on

Lumateperone (Caplyta)

drug

PRINCIPAL_INVESTIGATOR

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

trial

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

trial

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

trial

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

trial